To effectively support the goal of access for all citizens, we must consider all citizens. But delivering on that goal takes a commitment to understanding deeply who patients are, their needs, and how we can best support positive health outcomes. We need to start at the beginning and build into every decision we make and step we take the diverse socio economic and individual health considerations of each person we encounter.
Schneider Electric Foundation launched the Tomorrow Rising Fund to help vulnerable communities respond, recover and become more resilient in the wake of Covid-19
Schneider Electric’s people and partners across +60 countries have joined in by fundraising and volunteering to contribute to 65 projects which benefit +800,000 people
Following the initial emergency response, the fund continues to support education and professional training to secure the best future for young people and their communities
Press Release
Schneider Electric Foundation launched the Tomorrow Rising Fund to help vulnerable communities respond, recover and become more resilient in the wake of Covid-19
Schneider Electric’s people and partners across +60 countries have joined in by fundraising and volunteering to contribute to 65 projects which benefit +800,000 people
Following the initial emergency response, the fund continues to support education and professional training to secure the best future for young people and their communities
by Christa Myers, Process Engineer, and Marc Pelletier, PhD, Process Specialist
Blog
During a global pandemic, the pharmaceutical industry must juggle the need for speed and the need to protect patient safety. A strong regulatory strategy makes it possible to accelerate drug development without getting slowed down by compliance considerations.
As we enter into the 2020 election season, the way in which we participate has the potential to be impacted. From concerns around vote hacking to the fear of exposure to COVID-19, states are under increased scrutiny about how they will handle this year’s election. There is one thing that provides a good solution for both concerns – paper.
After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently given to patients intravenously through daily infusions in the hospital.
Along with the Society for Immunotherapy of Cancer we strive for a future #Immune2Cancer because to our team, cancer immunotherapy research is personal. Our scientists are researching potential, new cancer treatment options for our loved ones and yours.
COVID-19 is shaping new attitudes and behaviors among people, especially a growing awareness of health risks associated with hygiene in public spaces. According to a new international study from Tork®, an Essity brand, nearly eight out of ten people surveyed in North America feel more unsafe going to facilities with unhygienic public restrooms today than before the pandemic - and 33% of these respondents say they feel unsafe entering a restroom equipped with air dryers.
Press Release
COVID-19 is shaping new attitudes and behaviors among people, especially a growing awareness of health risks associated with hygiene in public spaces. According to a new international study from Tork®, an Essity brand, nearly eight out of ten people surveyed in North America feel more unsafe going to facilities with unhygienic public restrooms today than before the pandemic - and 33% of these respondents say they feel unsafe entering a restroom equipped with air dryers.
by Mark Paskanik, AIA, LEED AP BD+C, Senior Laboratory Planner
Article
Testing is a crucial component of our global response to COVID-19. The more people we can test for the virus, the better we can understand the threat we’re up against.
Producing enough tests and making them available to the public is just one half of this challenge. Processing the results quickly is the other.
